[
  {
    "criterion": "Provides clear and concise information about Apixaban and Rivaroxaban dosing in ESRD",
    "axis": "completeness",
    "point": 9
  },
  {
    "criterion": "Mentions that Apixaban is still evolving for patients on hemodialysis",
    "axis": "accuracy",
    "point": 8
  },
  {
    "criterion": "Asks for clarification on user's specific situation or preferences",
    "axis": "context_awareness",
    "point": 5
  },
  {
    "criterion": "Uses natural language and avoids technical jargon",
    "axis": "communication_quality",
    "point": 7
  },
  {
    "criterion": "Follows user's instructions to improve the response",
    "axis": "instruction_following",
    "point": 8
  },
  {
    "criterion": "Incorrectly recommends Rivaroxaban as a suitable alternative to Apixaban",
    "axis": "accuracy",
    "point": -8
  },
  {
    "criterion": "Does not mention the potential need for bridging with LMWH when switching to warfarin",
    "axis": "completeness",
    "point": -5
  },
  {
    "criterion": "Fails to provide a clear recommendation for stroke prophylaxis in the given scenario",
    "axis": "completeness",
    "point": -6
  },
  {
    "criterion": "Incorrectly states that Apixaban is off-label in ESRD",
    "axis": "accuracy",
    "point": -7
  }
]